Reaction

Which drugs are most reported with Heavy menstrual bleeding?

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 7,846 reports · 108 co-occurring drugs

As of the last recalculation, Heavy Menstrual Bleeding appears in 7,846 FAERS reports alongside 108 co-occurring drug terms. The strongest observed disproportionality signal is COPPER (PRR 111.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Copper	1,471	111.2	115.1
Etonogestrel	975	61.7	63.0
Tranexamic Acid	52	15.6	15.7
Levonorgestrel	969	14.4	14.5
Voclosporin	23	7.0	7.1
Eltrombopag Olamine	54	6.2	6.3
Progesterone	48	5.6	5.6
Romiplostim	27	4.8	4.8
Tretinoin	14	4.6	4.6
Iron	113	4.5	4.5
Ado-Trastuzumab Emtansine	14	4.4	4.4
Fremanezumab-Vfrm	19	4.4	4.4
Ketoprofen	20	4.1	4.1
Medroxyprogesterone Acetate	74	4.0	4.0
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, And Amphetamine Sulfate	51	3.9	3.9
Naltrexone Hydrochloride And Bupropion Hydrochloride	12	3.7	3.7
Etonogestrel And Ethinyl Estradiol	30	3.6	3.6
Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate And Amphetamine Aspartate	53	3.4	3.4
Calcium, Magnesium, Potassium, And Sodium Oxybates	11	3.4	3.4
Selexipag	31	3.2	3.2
Ferrous Sulfate	60	3.2	3.2
Alemtuzumab	23	3.2	3.2
Iron Sucrose	11	3.1	3.1
Hydroxyzine Hydrochloride	15	3.0	3.0
Hydroxyzine Hydrochloride Oral	15	3.0	3.0
Infliximab-Dyyb	33	3.0	3.0
Lisdexamfetamine Dimesylate	37	3.0	3.0
Amitriptyline Hydrochloride	19	2.9	2.9
Cladribine	10	2.8	2.8
Sertraline	118	2.7	2.7
Ofatumumab	33	2.6	2.6
Ocrelizumab	61	2.6	2.6
Cariprazine	9	2.6	2.6
Elexacaftor, Tezacaftor, And Ivacaftor	12	2.6	2.6
Ciclesonide	13	2.5	2.5
Propranolol Hydrochloride	63	2.3	2.3
Sumatriptan Succinate	22	2.3	2.3
Estradiol Gel 0.1%	38	2.2	2.2
Estradiol Transdermal	38	2.2	2.2
Venlafaxine	59	2.2	2.2
Hydroxyzine	39	2.2	2.2
Fluoxetine	53	2.1	2.1
Escitslopram	45	2.1	2.1
Escitalopram Oxalate	56	2.0	2.0
Vortioxetine	13	2.0	2.0
Galcanezumab-Gnlm	24	2.0	2.0
Labetalol	10	2.0	2.0
Tirzepatide	120	2.0	2.0
Ravulizumab	10	2.0	2.0
Macitentan	51	2.0	2.0
Sumatriptan	28	2.0	2.0
Zonisamide	10	1.8	1.8
Bupropion	30	1.8	1.8
Estradiol	57	1.8	1.8
Avapritinib	8	1.8	1.8
Aripiprazole Oral	27	1.7	1.7
Aripiprazole Orally Disintegrating	27	1.7	1.7
Vilazodone Hydrochloride	6	1.7	1.7
Methylphenidate Hydrochloride	37	1.7	1.7
Levocetirizine Dihydrochloride	15	1.7	1.7
Voxelotor	14	1.7	1.7
Misoprostol	6	1.6	1.6
Riociguat	20	1.6	1.6
Nilotinib	18	1.6	1.6
Rivaroxaban	125	1.6	1.6
Teriflunomide	27	1.6	1.6
Dexlansoprazole	24	1.5	1.5
Apixaban	38	1.5	1.5
Emicizumab	7	1.5	1.5
Drospirenone And Ethinyl Estradiol	25	1.5	1.5
Sildenafil	31	1.4	1.4
Baricitinib	5	1.4	1.4
Diroximel Fumarate	6	1.3	1.3
Asfotase Alfa	5	1.3	1.3
Oral Semaglutide	36	1.3	1.3
Pegvaliase-Pqpz	4	1.3	1.3
Methylphenidate	14	1.3	1.3
Treprostinil	58	1.2	1.2
Alpelisib	4	1.2	1.2
Fluticasone Furoate And Vilanterol Trifenatate	16	1.2	1.2
Upadacitinib	36	1.2	1.2
Leuprolide Acetate	34	1.2	1.2
Nintedanib	13	1.1	1.1
Vedolizumab	35	1.1	1.1
Pertuzumab	11	1.1	1.1
Encorafenib	4	1.1	1.1
Rimegepant Sulfate	5	1.0	1.0
Cabotegravir	3	1.0	1.0
Ozanimod Hydrochloride	3	1.0	1.0
Lumacaftor And Ivacaftor	3	0.9	0.9
Belimumab	11	0.9	0.9
Risankizumab-Rzaa	28	0.9	0.9
Siponimod	3	0.9	0.9
Brivaracetam	3	0.9	0.9
Dabrafenib	7	0.9	0.9
Cortisone Acetate	4	0.9	0.9
Isotretinoin	16	0.9	0.9
Nirmatrelvir And Ritonavir	17	0.8	0.8
Cannabidiol	7	0.8	0.8
Bimekizumab	6	0.7	0.7
Dasatinib	10	0.7	0.7
Ambrisentan	31	0.7	0.7
Sarilumab	6	0.6	0.6
Esketamine Hydrochloride	4	0.6	0.6
Dupilumab	106	0.6	0.6
Relugolix	5	0.6	0.6
Guselkumab	7	0.5	0.5
Erenumab-Aooe	9	0.4	0.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.